| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
|
AIDS
|
2007
|
1.85
|
|
2
|
Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis.
|
Ann Intern Med
|
2007
|
1.75
|
|
3
|
CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.
|
AIDS
|
2005
|
1.68
|
|
4
|
Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies.
|
PLoS Med
|
2011
|
1.42
|
|
5
|
Sex, politics, and religion: why AIDS is a secular issue.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2004
|
1.40
|
|
6
|
Twenty-five years of AIDS.
|
CMAJ
|
2006
|
1.39
|
|
7
|
The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.
|
Clin Pharmacol Ther
|
2004
|
1.33
|
|
8
|
Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV.
|
Clin Infect Dis
|
2005
|
1.32
|
|
9
|
Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection.
|
Clin Infect Dis
|
2002
|
1.30
|
|
10
|
Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.
|
Vaccine
|
2004
|
1.23
|
|
11
|
Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects.
|
Clin Pharmacokinet
|
2010
|
1.21
|
|
12
|
Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.
|
J Acquir Immune Defic Syndr
|
2009
|
1.19
|
|
13
|
Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa.
|
BMC Infect Dis
|
2006
|
1.07
|
|
14
|
Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10.
|
AIDS
|
2002
|
1.05
|
|
15
|
Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
|
J Clin Pharmacol
|
2006
|
1.02
|
|
16
|
Inaccuracy of death certificate diagnosis of tuberculosis and potential underdiagnosis of TB in a region of high HIV prevalence.
|
Clin Dev Immunol
|
2012
|
0.99
|
|
17
|
Development and validation of the HIV Medication Readiness Scale.
|
Assessment
|
2007
|
0.97
|
|
18
|
Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
|
AIDS
|
2006
|
0.97
|
|
19
|
The role of psychological and behavioral variables in quality of life and the experience of bodily pain among persons living with HIV.
|
J Pain Symptom Manage
|
2008
|
0.97
|
|
20
|
Systematic review of the effectiveness of training programs in writing for scholarly publication, journal editing, and manuscript peer review (protocol).
|
Syst Rev
|
2013
|
0.95
|
|
21
|
Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review.
|
Transfusion
|
2005
|
0.88
|
|
22
|
Inhibition of human cytochrome p450 metabolism by blended herbal products and vitamins.
|
J Pharm Pharm Sci
|
2011
|
0.87
|
|
23
|
Connection domain mutations in treatment-experienced patients in the OPTIMA trial.
|
J Acquir Immune Defic Syndr
|
2010
|
0.85
|
|
24
|
Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial.
|
PLoS One
|
2011
|
0.82
|
|
25
|
The Feasibility, Accuracy, and Impact of Xpert MTB/RIF Testing in a Remote Aboriginal Community in Canada.
|
Chest
|
2015
|
0.81
|
|
26
|
Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease.
|
J Acquir Immune Defic Syndr
|
2013
|
0.80
|
|
27
|
Health of prisoners, and the public health: no man is an island.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2004
|
0.80
|
|
28
|
Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review.
|
BMC Infect Dis
|
2014
|
0.79
|
|
29
|
Attenuated Salmonella typhimurium SL3261 as a vaccine vector for recombinant antigen in rabbits.
|
J Immunol Methods
|
2005
|
0.79
|
|
30
|
High HIV knowledge relates to low stigma in pharmacists and university health science students in Guyana, South America.
|
Int J Infect Dis
|
2010
|
0.79
|
|
31
|
In vitro and in vivo activity of combination antimicrobial agents on Haemophilus ducreyi.
|
J Antimicrob Chemother
|
2005
|
0.79
|
|
32
|
Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: a randomized, controlled trial.
|
Med Decis Making
|
2011
|
0.79
|
|
33
|
HIV pre-exposure prophylaxis (PrEP)--a quantitative ethics appraisal.
|
PLoS One
|
2011
|
0.78
|
|
34
|
Interpretation of undetectable hepatitis C virus RNA levels in HIV-hepatitis C virus co-infection.
|
AIDS
|
2004
|
0.78
|
|
35
|
Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers.
|
Antimicrob Agents Chemother
|
2008
|
0.78
|
|
36
|
Design and methods of the MAINTAIN study: a randomized controlled clinical trial of micronutrient and antioxidant supplementation in untreated HIV infection.
|
Contemp Clin Trials
|
2010
|
0.78
|
|
37
|
Tuberculosis elimination in the Canadian First Nations population: assessment by a state-transfer, compartmental epidemic model.
|
Int J Infect Dis
|
2009
|
0.77
|
|
38
|
Use of signature-tagged mutagenesis to identify virulence determinants in Haemophilus ducreyi responsible for ulcer formation.
|
J Microbiol Methods
|
2010
|
0.77
|
|
39
|
Effect of resveratrol on exercise capacity: a randomized placebo-controlled crossover pilot study.
|
Appl Physiol Nutr Metab
|
2014
|
0.76
|
|
40
|
Pharmaceutical gifts of medicine.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2004
|
0.75
|
|
41
|
The benefits and risks of bacille Calmette-Guérin vaccination among infants at high risk for both tuberculosis and severe combined immunodeficiency: assessment by Markov model.
|
BMC Pediatr
|
2006
|
0.75
|
|
42
|
On the zoonosis of M. avium subspecies paratuberculosis (MAP).
|
J Crohns Colitis
|
2012
|
0.75
|
|
43
|
Needs and prospects for HIV therapy in developing countries.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2002
|
0.75
|
|
44
|
Field evaluation of the Merlin immediate HIV-1 and -2 test for point-of-care detection of human immunodeficiency virus antibodies.
|
Clin Infect Dis
|
2002
|
0.75
|
|
45
|
The case for case reports.
|
Int J Infect Dis
|
2010
|
0.75
|
|
46
|
Epidemic HIV-associated Kaposi's sarcoma: not as common as it used to be.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2004
|
0.75
|
|
47
|
After terror, more horrors of war.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2002
|
0.75
|
|
48
|
Common dermatologic manifestations of herpesviruses in HIV/AIDS.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2004
|
0.75
|
|
49
|
Identification and characterization of a heme periplasmic-binding protein in Haemophilus ducreyi.
|
Biometals
|
2011
|
0.75
|
|
50
|
"Au Revoir les Enfants" without leadership for HIV treatment in poor countries.
|
J Int Assoc Physicians AIDS Care (Chic)
|
2003
|
0.75
|
|
51
|
Oral immunization using HgbA in a recombinant chancroid vaccine delivered by attenuated Salmonella typhimurium SL3261 in the temperature-dependent rabbit model.
|
J Immunol Methods
|
2011
|
0.75
|
|
52
|
Mouse viruses and human disease.
|
Lancet Infect Dis
|
2011
|
0.75
|